Felycin-CA1 (sirolimus delayed-release tablets) for Cats

What is Felycin-CA1 (sirolimus delayed-release tablets)?

Felycin‑CA1 is a once‑weekly sirolimus delayed‑release tablet used in cats with subclinical hypertrophic cardiomyopathy (HCM). It helps manage ventricular hypertrophy by slowing the abnormal thickening of the heart muscle associated with subclinical HCM. This medication is conditionally approved by the FDA for this specific use. Felycin-CA1 requires a prescription from your veterinarian.

Suitable for:

• Cats (Over 5.5 lbs, with subclinical Hypertrophic Cardiomyopathy)

Benefits:

• The first FDA conditionally-approved drug for the management of ventricular hypertrophy in cats with subclinical HCM.
• Felycin-CA1 is administered orally once-a-week for cats in small tablet sizes.
• Offers early intervention for cats with subclinical HCM.
• An affordable treatment option to manage subclinical HCM.
• Available in three strengths to ensure accurate administration for maximum efficacy.

How does Felycin-CA1 (sirolimus delayed-release tablets) work?

Sirolimus inhibits the mTOR pathway, which down‑regulates cellular growth and hypertrophic signaling in cardiac muscle. By modulating this pathway, the drug helps slow progressive thickening of the left ventricular wall in subclinical HCM.

Caution:

Felycin®-CA1 is a prescription medication that requires veterinary authorization before use. Do not use in cats diagnosed with diabetes mellitus, as usage has been linked to fatal diabetic ketoacidosis. Do not administer in cats with pre-existing liver disease. If a cat is diagnosed with diabetes at any point during the course of treatment, the medication must be discontinued immediately.

How should I store this product?

Store in a cool, dry place between 68 F - 77 F (20 C - 25 C). Excursions between 59 F - 86 F (15 C - 30 C) are permitted. Keep Felycin-CA1 in a secure location out of reach of dogs, cats and other animals to prevent accidental ingestion of overdose. Keep out of reach of children. Contact a physician in case of accidental ingestion by humans.

What is the most important information I should know about Felycin-CA1 (sirolimus delayed-release tablets)?

This is a once-weekly medication specifically developed for the management of heart wall thickening in cats with subclinical hypertrophic cardiomyopathy (HCM). It is intended to potentially slow the progression of heart disease before your cat shows outward symptoms. A prescription from your veterinarian is required.

What should I discuss with my veterinarian before giving Felycin-CA1 (sirolimus delayed-release tablets) to my pet?

Confirm your cat has had an echocardiogram to verify they are in the subclinical stage of HCM. You should discuss if your cat has kidney disease, hyperthyroidism, chronic viral diseases, or is currently receiving beta-blockers or corticosteroids. The use of Felycin-CA1 in cats with viral disease like feline viral rhinotracheitis has not been evaluated. Its effectiveness has not been evaluated in sexually intact cats, therefore, should not be used in animals intended for breeding. Treatment with Felycin-CA1 could impact the cat’s ability to mount an adequate immune response to vaccinations.

How should Felycin-CA1 (sirolimus delayed-release tablets) for Cats be given/administered?

This medication should be given orally once weekly in conjunction with a meal. Always store tablets in the original packaging and only remove the required number of tablets from the blister at the time of dosing. Tablets must be swallowed whole; do not split, crush, or chew them, as this destroys the delayed-release coating. Affecting this coating would not only change the absorption profile but also risk human exposure to the active ingredient sirolimus (rapamycin). Avoid direct contact with vomit, saliva, and tablet remnants. When cleaning up vomit, saliva, or tablet remnants, wear gloves and wash hands afterwards. Dispose of any tablets that are not swallowed by your cat.

What are the potential side effects of Felycin-CA1 (sirolimus delayed-release tablets)?

The most frequently observed adverse reactions in cats treated with Felycin-CA1 were cardiovascular in nature, relating to the progression of HCM, and included arrhythmia, congestive heart failure, syncope, and pericardial effusion. Other adverse reactions observed were lethargy, vomiting, diarrhea, and a lack of appetite. Treatment has been associated with the elevation of transaminase enzymes, specifically alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and owners should monitor for clinical signs of liver dysfunction. Bloodwork should be repeated 1 to 2 months following initiation of treatment, and every 6 to 12 months thereafter. Discontinue treatment if transaminase values exceed 2X the upper limit of normal (ULN), if other liver enzymes besides ALT or AST are elevated, or if clinical signs of liver dysfunction are noted.

What happens if I miss giving a dose of Felycin-CA1 (sirolimus delayed-release tablets) for Cats?

Missing a dose of Felycin-CA1 will not cause any immediate problems for your cat. If you happen to miss a dose, wait until the next week to give the regularly scheduled dose so you can stay on a consistent schedule.

What happens if I overdose my pet on Felycin-CA1 (sirolimus delayed-release tablets) for Cats?

Contact your veterinarian immediately or the nearest vet hospital. You can also contact ASPCA 24/7 Poison Control Hotline at 888-426-4435 or the Pet Poison Helpline at 855-764-7661. Overdose may lead to increased risks of liver toxicity or immunosuppression.

What special precautions are there?

Bloodwork must be repeated 1 to 2 months following the start of treatment and every 6 to 12 months thereafter. Pregnant and breastfeeding women should avoid contact with Felycin-CA1. People with known hypersensitivity to sirolimus should administer Felycin-CA1 with caution — wear gloves when handling and wash hands afterwards.

What should I avoid while giving Felycin-CA1 (sirolimus delayed-release tablets) for Cats to my pet?

Avoid vaccinating your cat without consulting your vet first, as the medication's impact on many vaccines has not been evaluated. Avoid administering this drug to cats already showing signs of active heart failure (Stage C or D). No studies have been completed to support efficacy in patients with clinical and late-stage cardiac disease. In addition, cats in congestive heart failure may need to start other medications, and no studies have been done to test for using those medications along with Felycin-CA1. Therefore, continued treatment with Felycin-CA1 in a patient with congestive heart failure would be considered off-label, which is not recommended.

What other drugs will affect Felycin-CA1 (sirolimus delayed-release tablets) for Cats?

Certain medications can change how Felycin®-CA1 works or increase the risk of side effects, so your veterinarian needs a full list of everything your cat takes. Be especially careful with heart medications like calcium channel blockers or amiodarone, as well as antifungal treatments and immune system suppressants like cyclosporine. You should also consult your vet before using common parasite treatments (such as eprinomectin or emodepside) alongside this drug. Since it is unknown how Felycin®-CA1 interacts with steroids or beta-blockers, these combinations require close monitoring. While this medication was shown not to interfere with the rabies vaccine, its impact on other common feline vaccinations (such as FHV-1, FCV, FPV, and FeLV) is currently unknown.